doi: 10.1161/CIRCULATIONAHA.104.532499
(Circulation. 2005;112:3375-3383.)
© 2005 American Heart Association, Inc.
Coronary Heart Disease |
Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men
From the Departments of Nutrition (T.P., F.M.S., M.J.S., E.B.R.) and Epidemiology (T.P., M.J.S., E.B.R.), Harvard School of Public Health, Boston, Mass; Channing Laboratory (F.M.S., M.J.S., E.B.R.), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Department of Laboratory Medicine (N.R.), Children’s Hospital and Department of Pathology, Harvard Medical School, Boston, Mass; the Department of Epidemiology (T.P.), German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany; and the Department of Epidemiology (C.J.G.), Merck Research Laboratories, West Point, Pa.
Correspondence to Dr Tobias Pischon, Department of Epidemiology, German Institute of Human Nutrition (DIfE), Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany. E-mail pischon{at}mail.dife.de
Received December 27, 2004; revision received August 4, 2005; accepted August 8, 2005.
Background— Apolipoprotein B (apoB) plasma levels reflect the concentration of proatherogenic lipoproteins very low-density lipoprotein and low-density lipoprotein (LDL), whereas non–high-density lipoprotein cholesterol (non–HDL-C) levels reflect the concentration of cholesterol transported by these particles.
Methods and Results— The aim of our study was to compare apoB, non–HDL-C, LDL cholesterol (LDL-C), and other lipid markers as predictors of coronary heart disease (CHD) in a nested case-control study among 18 225 participants in the Health Professionals Follow-up Study. Among men who were free of diagnosed cardiovascular disease at the time of blood collection, 266 had nonfatal myocardial infarction or fatal CHD during 6 years of follow-up. Through the use of risk set sampling, control subjects were selected at a 2:1 ratio and matched with regard to age, date of blood collection, and smoking status. After adjustment for matching factors, the relative risk of CHD in the highest quintile compared with the lowest quintile was 2.76 (95% confidence interval [CI], 1.66 to 4.58) for non–HDL-C, 3.01 (95% CI, 1.81 to 5.00) for apoB, 1.81 (95% CI, 1.12 to 2.93) for LDL-C, 0.31 (95% CI, 0.18 to 0.52) for HDL-C, 2.41 (95% CI, 1.43 to 4.07) for triglycerides (all P trend <0.001), and 1.42 (95% CI, 0.86 to 2.32, P trend =0.19) for lipoprotein(a). When non–HDL-C and LDL-C were mutually adjusted, only non–HDL-C was predictive of CHD. When non–HDL-C and apoB were mutually adjusted, only apoB was predictive; the relative risk was 4.18 (95% CI, 1.30 to 13.49; P trend =0.02) for apoB compared with 0.70 (95% CI, 0.21 to 2.27; P trend =0.72) for non–HDL-C. Triglycerides added significant information to non–HDL-C but not to apoB for CHD risk prediction.
Conclusions— Although non–HDL-C and apoB were both strong predictors of CHD in this male cohort, more so than LDL-C, the findings support the concept that the plasma concentration of atherogenic lipoprotein particles measured by apoB is more predictive in development of CHD than the cholesterol carried by these particles, measured by non–HDL-C.
Key Words: apolipoproteins • coronary disease • follow-up studies • lipids • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  M. Juonala, J. S.A. Viikari, M. Kahonen, T. Solakivi, H. Helenius, A. Jula, J. Marniemi, L. Taittonen, T. Laitinen, T. Nikkari, et al. Childhood Levels of Serum Apolipoproteins B and A-I Predict Carotid Intima-Media Thickness and Brachial Endothelial Function in Adulthood: The Cardiovascular Risk in Young Finns Study J. Am. Coll. Cardiol., July 22, 2008; 52(4): 293 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Hsue, K. Squires, A. F. Bolger, B. Capili, G. A. Mensah, Z. Temesgen, C. A. Wanke, D. A. Wohl, and for Working Group 4 Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients Circulation, July 8, 2008; 118(2): e41 - e47. [Full Text] [PDF]
|
|
|
|
|
|
J. J.P. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, et al. Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment Circulation, June 10, 2008; 117(23): 3002 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Albers, S. M. Marcovina, G. Imperatore, B. M. Snively, J. Stafford, W. Y. Fujimoto, E. J. Mayer-Davis, D. B. Petitti, C. Pihoker, L. Dolan, et al. Prevalence and Determinants of Elevated Apolipoprotein B and Dense Low-Density Lipoprotein in Youths with Type 1 and Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Fernandez and D. Webb The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk J. Am. Coll. Nutr., February 1, 2008; 27(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Chien, H.-C. Hsu, T.-C. Su, M.-F. Chen, Y.-T. Lee, and F. B. Hu Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese J. Lipid Res., November 1, 2007; 48(11): 2499 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Allison, E. O. Lillie, D. DiTomasso, C. M. Wright, and M. H. Criqui Renal Artery Calcium Is Independently Associated With Hypertension J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1578 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tirosh, A. Rudich, T. Shochat, D. Tekes-Manova, E. Israeli, Y. Henkin, I. Kochba, and I. Shai Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men Ann Intern Med, September 18, 2007; 147(6): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell Hypertriglyceridemia N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, E. J. Schaefer, J. H. Contois, J. R. McNamara, L. Sullivan, M. J. Keyes, M. J. Pencina, C. Schoonmaker, P. W. F. Wilson, R. B. D'Agostino, et al. Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women JAMA, August 15, 2007; 298(7): 776 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kahn Metabolic Syndrome: Is It a Syndrome? Does It Matter? Circulation, April 3, 2007; 115(13): 1806 - 1811. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mazzone, P. M. Meyer, G. T. Kondos, M. H. Davidson, S. B. Feinstein, R. B. D'Agostino Sr., A. Perez, and S. M. Haffner Relationship of Traditional and Nontraditional Cardiovascular Risk Factors to Coronary Artery Calcium in Type 2 Diabetes Diabetes, March 1, 2007; 56(3): 849 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, J. E. Buring, N. Rifai, and N. R. Cook Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score JAMA, February 14, 2007; 297(6): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wu, W. C. Willett, N. Rifai, I. Shai, J. E. Manson, and E. B. Rimm Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Davis and K. J. Mukamal Hypothesis Testing: Means Circulation, September 5, 2006; 114(10): 1078 - 1082. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Hankey Potential New Risk Factors for Ischemic Stroke: What Is Their Potential? Stroke, August 1, 2006; 37(8): 2181 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Sniderman Apolipoprotein B Versus Non-High-Density Lipoprotein Cholesterol: And the Winner Is... Circulation, November 29, 2005; 112(22): 3366 - 3367. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Denke Weighing in Before the Fight: Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B as the Best Predictor for Coronary Heart Disease and the Best Measure of Therapy Circulation, November 29, 2005; 112(22): 3368 - 3370. [Full Text] [PDF]
|
|